Endothelial dysfunction in axial spondyloarthritis associated with inflammatory bowel disease

Abstract

Spondyloarthritis is a group of musculoskeletal inflammatory diseases, including axial and peripheral forms. The current classification of these diseases emphasizes the diagnostic importance of the well-known association between spondyloarthritis and inflammatory bowel diseases (Crohn’s disease and ulcerative colitis). According to many large clinical studies, both spondyloarthritis and inflammatory bowel diseases demonstrate increased cardiovascular risk, but the underlying mechanisms are not entirely clear. One of the possible ways to involve the cardiovascular system in these diseases is supposed to be the formation of endothelial vascular dysfunction developing in many inflammatory and non-inflammatory conditions. At the same time, endothelial dysfunction needs to be analyzed multidimensionally due to its participation in regulation of many processes, such as the providing of vascular tone, cell migration, angiogenesis, and hemostasis.

This review examines the latest data on endothelial dysfunction in axial spondyloarthritis and inflammatory bowel diseases, and separately analyzes the studies of this phenomenon in patients with inflammatory bowel diseases-associated axial spondyloarthritis. Special attention is paid to modern laboratory and instrumental methods for assessing endothelial function and their potential diagnostic significance in clinical practice.

Keywords

axial spondyloarthritis / inflammatory bowel diseases / Crohn’s disease / ulcerative colitis / endothelium / cardiovascular risk factors

References

[1] Klinicheskaya revmatologiya. Rukovodstvo dlya vrachei. Ed. by V.I. Mazurov. 3rd ed. Moscow: E-noto; 2021. (In Russ.)

[2] Клиническая ревматология. Руководство для врачей / под ред. В.И. Мазурова. 3-е изд., перераб. и доп. Москва: Е-ното, 2021.

[3] Erdes ShF, Rebrov AP, Dubinina TV, et al. Spondyloarthritis: modern terminology and definitions. Therapeutic Archive. 2019;91(5):84–88. (In Russ.). DOI: 10.26442/00403660.2019.05.000208

[4] Эрдес Ш.Ф., Ребров А.П., Дубинина Т.В. и др. Спондилоартриты: современная терминология и определения // Терапевтический архив. 2019.Т. 91, № 5. С. 84–88. DOI: 10.26442/00403660. 2019.05.000208

[5] Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol. 2010;22(4):375–380. DOI:10.1097/bor.0b013e32833ac5cc

[6] Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis // Curr. Opin.Rheumatol. 2010. Vol. 22, No. 4. P. 375–380. DOI:10.1097/bor.0b013e32833ac5cc

[7] Psoriaticheskie i enteropaticheskie artropatii (M07*) [Internet]. Mezhdunarodnaya klassifikatsiya boleznei 10 peresmotra (MKB-10). Available from: https://mkb-10.com/index.php?pid=12048. Accessed: June 21, 2022. (In Russ).

[8] Псориатические и энтеропатические артропатии (M07*) [Электронный ресурс] // Международная классификация болезней 10 пересмотра (МКБ-10). Режим доступа: https://mkb-10.com/index.php?pid=12048. Дата обращения: 21.06.2022.

[9] Harbord M, Annese V, Vavricka SR, et al. The First European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–254. DOI:10.1093/ecco-jcc/jjv213

[10] Harbord M., Annese V., Vavricka S.R. et al. The First European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease // J. Crohns Colitis. 2016. Vol. 10, No. 3. P. 239–254. DOI:10.1093/ecco-jcc/jjv213

[11] Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410. DOI:10.1177/1759720x20939410

[12] Di Jiang C., Raine T. IBD considerations in spondyloarthritis //Ther. Adv. Musculoskelet. Dis. 2020. Vol. 12. P. 1759720X20939410.DOI:10.1177/1759720x20939410

[13] Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73(6):1186–1189. DOI:10.1136/annrheumdis-2013-203854

[14] Van Praet L., Jans L., Carron P. et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort // Ann. Rheum. Dis. 2014. Vol. 73, No. 6. P. 1186–1189. DOI:10.1136/annrheumdis-2013-203854

[15] Karreman MC, Luime JJ, Hazes JM, Weel AE. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis. J Crohns Colitis. 2017;11(5):631–642. DOI: 10.1093/ecco-jcc/jjw199

[16] Karreman M.C., Luime J.J., Hazes J.M., Weel A.E. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis // J. Crohns Colitis. 2017. Vol. 11, No. 5. P. 631–642.DOI:10.1093/ecco-jcc/jjw199

[17] Evans J, Sapsford M, McDonald S, et al. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: A systematic literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720x21996973. DOI: 10.1177/1759720x21996973

[18] Evans J., Sapsford M., McDonald S. et al. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: A systematic literature review // Ther. Adv. Musculoskelet. Dis. 2021. Vol. 13. P. 1759720x21996973. DOI:10.1177/1759720x21996973

[19] Belousova EN, Odintsova OH, Protopopov MS, Abdulganieva DI. ASAS criteria for inflammatory back pain: diagnostic significance in patients with inflammatory bowel disease. Rheumatology Science and Practice. 2019;57(2):175–179. (In Russ.). DOI: 10.14412/1995-4484-2019-175-179

[20] Белоусова Е.Н., Одинцова А.Х., Протопопов М.С., Абдулганиева Д.И. Критерии воспалительной боли в спине ASAS: диагностическая значимость у пациентов с воспалительными заболеваниями кишечника // Научно-практическая ревматология. 2019. Т. 57, № 2. С. 175–179. DOI: 10.14412/1995-4484-2019-175-179

[21] Kumar A, Lukin D, Battat R, et al. Defining the phenotype, pathogenesis and treatment of Crohn’s disease associated spondyloarthritis. J Gastroenterol. 2020;55(7):667–678. DOI: 10.1007/s00535-020-01692-w

[22] Kumar A., Lukin D., Battat R. et al. Defining the phenotype, pathogenesis and treatment of Crohn’s disease associated spondyloarthritis // J. Gastroenterol.2020. Vol. 55, No. 7. P. 667–678. DOI: 10.1007/s00535-020-01692-w

[23] Fantini MC, Pallone F, Monteleone G. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol. 2009;15(20):2472. DOI: 10.3748/wjg.15.2472

[24] Fantini M.C., Pallone F., Monteleone G. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies // World J. Gastroenterol. 2009. Vol. 15, No. 20. P. 2472. DOI: 10.3748/wjg.15.2472

[25] Kim JH, Choi IA. Cardiovascular morbidity and mortality in patients with spondyloarthritis: A meta-analysis. Int J Rheum Dis. 2021;24(4):477–486. DOI: 10.1111/1756-185x.13970

[26] Kim J.H., Choi I.A. Cardiovascular morbidity and mortality in patients with spondyloarthritis: A meta-analysis // Int. J. Rheum. Dis. 2021. Vol. 24, No. 4. P. 477–486. DOI: 10.1111/1756-185x.13970

[27] Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016;75(6):1016–1023. DOI: 10.1136/annrheumdis-2015-208174

[28] Moltó A., Etcheto A., van der Heijde D. et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study // Ann. Rheum. Dis. 2016. Vol. 75, No. 6. P. 1016–1023. DOI: 10.1136/annrheumdis-2015-208174

[29] Gaidukova IZ, Rebrov AP. The risk of coronary artery disease development in patients with ankylosing spondylitis (Bechterew’s disease) and psoriatic arthritis: a 10-year prospective follow-up study. The Clinician. 2016;10(3):26–31. (In Russ.). DOI: 10.17650/1818-8338-2016-10-3-26-31

[30] Гайдукова И.З., Ребров А.П. Риск появления ишемической болезни сердца у больных анкилозирующим спондилитом (болезнью Бехтерева) и псориатическим артритом по результатам десятилетнего проспективного наблюдения (исследование ПРОГРЕСС) // Клиницист. 2016. Т. 10, № 3. С.26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31

[31] Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–1925. DOI: 10.1136/ard.2011.151191

[32] Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity // Ann. Rheum.Dis. 2011. Vol. 70, No. 11. P. 1921–1925. DOI: 10.1136/ard.2011.151191

[33] Vasilenko EA, Mazurov VI, Gaidukova IZ, et al. Interleukin-17 effect on the pathogenesis and risks of cardiovascular diseases in spondylarthritis. RMJ. 2020;(11):39–42. (In Russ.)

[34] Василенко Е.А., Мазуров В.И., Гайдукова И.З. и др. Влияние интерлейкина-17 на патогенез и риски развития сердечно-сосудистых заболеваний при спондилоартритах // РМЖ. 2020. №11. С. 39–42.

[35] Gravina AG, Dallio M, Masarone M, et al. Vascular endothelial dysfunction in inflammatory bowel diseases: pharmacological and nonpharmacological targets. Oxid Med Cell Longev. 2018;2018:2568569. DOI: 10.1155/2018/2568569

[36] Gravina A.G., Dallio M., Masarone M. et al. Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets // Oxid. Med. Cell. Longev. 2018. Vol. 2018. P. 2568569. DOI: 10.1155/2018/2568569

[37] Ehrenpreis ED, Zhou Y, Alexoff A, Melitas C. Effect of the diagnosis of inflammatory bowel disease on risk-adjusted mortality in hospitalized patients with acute myocardial infarction, congestive heart failure and pneumonia. PLoS One. 2016;11(7):e0158926. DOI: 10.1371/journal.pone.0158926

[38] Ehrenpreis E.D., Zhou Y., Alexoff A., Melitas C. Effect of the diagnosis of inflammatory bowel disease on risk-adjusted mortality in hospitalized patients with acute myocardial infarction, congestive heart failure and pneumonia // PLoS One. 2016. Vol. 11, No. 7. P. e0158926. DOI: 10.1371/journal.pone.0158926

[39] Ruisi P, Makaryus JN, Ruisi M, Makaryus AN. Inflammatory bowel disease as a risk factor for premature coronary artery disease. J Clin Med Res. 2015;7(4):257–261. DOI: 10.14740/jocmr2102w

[40] Ruisi P., Makaryus J.N., Ruisi M., Makaryus A.N. Inflammatory bowel disease as a risk factor for premature coronary artery disease // J. Clin. Med. Res. 2015. Vol. 7, No. 4. P. 257–261. DOI: 10.14740/jocmr2102w

[41] Schicho R, Marsche G, Storr M. Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets. 2015;16(3):181–188. DOI: 10.2174/1389450116666150202161500

[42] Schicho R., Marsche G., Storr M. Cardiovascular complications in inflammatory bowel disease // Curr. Drug. Targets. 2015. Vol. 16, No. 3. P. 181–188. DOI: 10.2174/1389450116666150202161500

[43] Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6(1):41–45. DOI: 10.1016/j.cgh.2007.09.016

[44] Bernstein C.N., Wajda A., Blanchard J.F. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study // Clin. Gastroenterol. Hepatol. 2008. Vol. 6, No. 1. P. 41–45. DOI: 10.1016/j.cgh.2007.09.016

[45] Feng W, Chen G, Cai D, et al. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J Am Heart Assoc. 2017;6(8):e005892. DOI: 10.1161/JAHA.117.005892

[46] Feng W., Chen G., Cai D. et al. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies // J. Am. Heart Assoc. 2017. Vol. 6, No. 8. P. e005892. DOI: 10.1161/JAHA.117.005892

[47] Rungoe C, Basit S, Ranthe MF, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62(5):689–694. DOI: 10.1136/gutjnl-2012-303285

[48] Rungoe C., Basit S., Ranthe M.F. et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study // Gut. 2013. Vol. 62, No. 5. P. 689–694. DOI: 10.1136/gutjnl-2012-303285

[49] Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure. Circ Heart Fail. 2014;7(5):717–722. DOI: 10.1161/circheartfailure.114.001152

[50] Kristensen S.L., Ahlehoff O., Lindhardsen J. et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure //Circ. Heart Fail. 2014. Vol. 7, No. 5. P. 717–722. DOI: 10.1161/circheartfailure.114.001152

[51] Czubkowski P, Osiecki M, Szymańska E, Kierkuś J. The risk of cardiovascular complications in inflammatory bowel disease. Clin Exp Med. 2020;20(4):481–491. DOI: 10.1007/s10238-020-00639-y

[52] Czubkowski P., Osiecki M., Szymańska E., Kierkuś J. The risk of cardiovascular complications in inflammatory bowel disease // Clin. Exp. Med. 2020. Vol. 20, No. 4. P. 481–491. DOI: 10.1007/s10238-020-00639-y

[53] Andersen NN, Jess T. Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2014;5(3):359–365. DOI: 10.4291/wjgp.v5.i3.359

[54] Andersen N.N., Jess T. Risk of cardiovascular disease in inflammatory bowel disease // World J. Gastrointest. Pathophysiol. 2014. Vol. 5, No. 3. P. 359–365. DOI: 10.4291/wjgp.v5.i3.359

[55] Azevedo VF, Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int. 2010;30(11):1411–1416. DOI: 10.1007/s00296-010-1416-3

[56] Azevedo V.F., Pecoits-Filho R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis // Rheumatol. Int. 2010. Vol. 30, No. 11. P. 1411–1416. DOI: 10.1007/s00296-010-1416-3

[57] Dubikov AI, Cherepovsky AA, Belogolovyh LA, et al. Role of nitric oxide in musculoskeletal system diseases (part II). Rheumatology Science and Practice. 2004;42(4):53–56. (In Russ.). DOI: 10.14412/1995-4484-2004-803

[58] Дубиков А.И., Череповский А.В., Белоголовых Л.А. и др. Роль оксида азота в патологии опорно-двигательного аппарата (часть II) // Научно-практическая ревматология. 2004. Т. 42, № 4. С. 53–56. DOI: 10.14412/1995-4484-2004-803

[59] Kubes P, McCafferty DM. Nitric oxide and intestinal inflammation. Am J Med. 2000;109(2):150–158. DOI: 10.1016/s0002-9343(00)00480-0

[60] Kubes P., McCafferty D.M. Nitric oxide and intestinal inflammation // Am. J. Med. 2000. Vol. 109, No. 2. P. 150–158. DOI: 10.1016/s0002-9343(00)00480-0

[61] Soufli I, Toumi R, Rafa H, Touil-Boukoffa C. Cytokines and nitric oxide in immunopathogenesis of IBD and potential therapeutic approaches. In: New Insights into Inflammatory Bowel Disease. Intechopen; 2016. DOI: 10.5772/65001

[62] Soufli I., Toumi R., Rafa H., Touil-Boukoffa C. Cytokines and nitric oxide in immunopathogenesis of IBD and potential therapeutic approaches //New Insights into Inflammatory Bowel Disease. Intechopen, 2016. DOI: 10.5772/65001

[63] Kalinin RE, Suchkov IA, Korotkova NV, et al. The research of the molecular mechanisms of endothelial dysfunction in vitro. Genes and Cells. 2019;14(1):22–32. (In Russ.). DOI: 10.23868/201903003

[64] Калинин Р.Е., Сучков И.А., Короткова Н.В. и др. Изучение молекулярных механизмов эндотелиальной дисфункции in vitro // Гены и Клетки. 2019. Т. 14, №1. С. 22–32. DOI: 10.23868/201903003

[65] Stepanova TV, Ivanov AN, Popyhova EB, Lagutina DD. Moleculare markers of the endothelial dysfunction. Modern problems of science and education. 2019;(1):1–9. (In Russ.)

[66] Степанова Т.В., Иванов А.Н., Попыхова Э.Б., Лагутина Д.Д. Молекулярные маркеры эндотелиальной дисфункции // Современные проблемы науки и образования. 2019. № 1. С. 1–9.

[67] Onmaz DE, Isik K, Sivrikaya A, et al. Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis. Amino Acids. 2021;53(9):1329–1338. DOI: 10.1007/s00726-021-03046-z

[68] Onmaz D.E., Isik K., Sivrikaya A. et al. Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis // Amino Acids. 2021. Vol. 53, No. 9. P. 1329–1338. DOI: 10.1007/s00726-021-03046-z

[69] de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255(5047):989–991. DOI: 10.1126/science.1312256

[70] de Vries C., Escobedo J.A., Ueno H. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor // Science. 1992. Vol. 255, No. 5047. P. 989–991. DOI: 10.1126/science.1312256

[71] Speirs V, Atkin SL. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer. 1999;80(5–6):898–903. DOI: 10.1038/sj.bjc.6690438

[72] Speirs V., Atkin S.L. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours // Br. J. Cancer. 1999. Vol. 80, No. 5–6. P. 898–903.DOI: 10.1038/sj.bjc.6690438

[73] Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18(28):4266–4288. DOI: 10.2174/138161212802481237

[74] Tuttolomondo A., Di Raimondo D., Pecoraro R. et al. Atherosclerosis as an inflammatory disease // Curr. Pharm.Des. 2012. Vol. 18, No. 28. P. 4266–4288. DOI: 10.2174/138161212802481237

[75] Malakhova ZL, Vlasov TD, Vasina EYu, et al. Comparison of sensitivity of various methods in the assessment of endothelium-dependent vasodilation. Proceedings of the 12-ya mezhdunarodnaya konferentsiya “Mikrotsirkulyatsiya i gemoreologiya: ot fundamental’nykh issledovanii v klinicheskuyu praktiku”. Yaroslavl’: Kancler; 2019. P. 42. (In Russ.)

[76] Малахова З.Л., Власов Т.Д., Васина Е.Ю. и др. Сравнение чувствительности различных методов исследования эндотелийзависимой вазодилатации // 12-я международная конференция “Микроциркуляция и гемореология: от фундаментальных исследований в клиническую практику”: тезисы докладов. Ярославль: Канцлер, 2019. С. 42.

[77] Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: A position statement from the European Society of Cardiology Working Group on peripheral circulation. Eur J Cardiovasc Prev Rehabil. 2011;18(6):775–789. DOI: 10.1177/1741826711398179

[78] Lekakis J., Abraham P., Balbarini A. et al. Methods for evaluating endothelial function: A position statement from the European Society of Cardiology Working Group on peripheral circulation //Eur. J. Cardiovasc. Prev.Rehabil. 2011. Vol. 18, No. 6. P. 775–789. DOI: 10.1177/1741826711398179

[79] Triantafyllou C, Nikolaou M, Ikonomidis I, et al. Effects of anti-inflammatory treatment and surgical intervention on endothelial glycocalyx, peripheral and coronary microcirculatory function and myocardial deformation in inflammatory bowel disease patients: A two-arms two-stage clinical trial. Diagnostics (Basel). 2021;11(6):993. DOI: 10.3390/diagnostics11060993

[80] Triantafyllou C., Nikolaou M., Ikonomidis I. et al. Effects of anti-inflammatory treatment and surgical intervention on endothelial glycocalyx, peripheral and coronary microcirculatory function and myocardial deformation in inflammatory bowel disease patients: A two-arms two-stage clinical trial // Diagnostics (Basel). 2021. Vol. 11, No. 6. P. 993. DOI: 10.3390/diagnostics11060993

[81] Vlasov TD, Lazovskaya OA, Shimanski DA, et al. The endothelial glycocalyx: research methods and prospects for their use in endothelial dysfunction assessment. Regional blood circulation and microcirculation. 2020;19(1):5–16. (In Russ.). DOI: 10.24884/1682-6655-2020-19-1-5-16

[82] Власов Т.Д., Лазовская О.А., Шиманьски Д.А. и др. Эндотелиальный гликокаликс: методы исследования и перспективы их применения при оценке дисфункции эндотелия // Регионарное кровообращение и микроциркуляция. 2020. Т. 19, № 1. С. 5–16. DOI: 10.24884/1682-6655-2020-19-1-5-16

[83] Baryshnikov EN. Clinical and prognostic value of nitric oxide in inflammatory bowel diseases (clinical and experimental study) [dissertation]. Moscow; 2008. (In Russ.)

[84] Барышников Е.Н. Клиническое и прогностическое значение оксида азота при воспалительных заболеваниях кишечника (клинико-экспериментальное исследование): дисс. … канд. мед. наук. Москва, 2008.

[85] Avdagić N, Zaćiragić A, Babić N, et al. Nitric oxide as a potential biomarker in inflammatory bowel disease. Bosn J Basic Med Sci. 2013;13(1):5–9. DOI: 10.17305/bjbms.2013.2402

[86] Avdagić N., Zaćiragić A., Babić N. et al. Nitric oxide as a potential biomarker in inflammatory bowel disease // Bosn. J. Basic. Med. Sci. 2013. Vol. 13, No. 1. P. 5–9. DOI: 10.17305/bjbms.2013.2402

[87] Iwashita E, Miyahara T, Hino K, et al. High nitric oxide synthase activity in endothelial cells in ulcerative colitis. J Gastroenterol. 1995;30(4):551–554. DOI: 10.1007/BF02347578

[88] Iwashita E., Miyahara T., Hino K. et al. High nitric oxide synthase activity in endothelial cells in ulcerative colitis // J. Gastroenterol. 1995. Vol. 30, No. 4. P. 551–554. DOI: 10.1007/BF02347578

[89] Palatka K, Serfőző Z, Veréb Z, et al. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease. Scand J Gastroenterol. 2005;40(6):670–680. DOI: 10.1080/00365520510015539

[90] Palatka K., Serfőző Z., Veréb Z. et al. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease // Scand. J. Gastroenterol. 2005. Vol. 40, No. 6. P. 670–680. DOI: 10.1080/00365520510015539

[91] Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010;16(1):52–57. DOI: 10.1002/ibd.20994

[92] Owczarek D., Cibor D., Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases // Inflamm. Bowel. Dis. 2010. Vol. 16, No. 1. P. 52–57. DOI: 10.1002/ibd.20994

[93] Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):G5–G18. DOI: 10.1152/ajpgi.00107.2007

[94] Chidlow J.H. Jr., Shukla D., Grisham M.B., Kevil C.G. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues // Am. J. Physiol. Gastrointest. Liver Physiol. 2007. Vol. 293, No. 1. P. G5–G18. DOI: 10.1152/ajpgi.00107.2007

[95] Stepina EA. Clinical and laboratory indicators of endothelial function and their diagnostic significance in inflammatory bowel diseases [dissertation]. Perm’; 2016. (In Russ.)

[96] Степина Е.А. Клинико-лабораторные показатели функции эндотелия и их диагностическая значимость при воспалительных заболеваниях кишечника: дисс. канд. мед. наук. Пермь, 2016.

[97] Yu W, Hegarty JP, Berg A, et al. Nkx2-3 transcriptional regulation of endothelin-1 and VEGF signaling in human intestinal microvascular endothelial cells. PLoS One. 2011;6(5):e20454. DOI: 10.1371/journal.pone.0020454

[98] Yu W., Hegarty J.P., Berg A. et al. Nkx2-3 transcriptional regulation of endothelin-1 and VEGF signaling in human intestinal microvascular endothelial cells //PLoS One. 2011. Vol. 6, No. 5. P. e20454. DOI: 10.1371/journal.pone.0020454

[99] Dueñas Pousa I, Maté Jiménez J, Salcedo Mora X, et al. Analysis of soluble angiogenic factors in Crohn’s disease: A preliminary study. Gastroenterol Hepatol. 2007;30(9):518–524. DOI: 10.1157/13111682

[100] Dueñas Pousa I., Maté Jiménez J., Salcedo Mora X. et al. Analysis of soluble angiogenic factors in crohn’s disease: A preliminary study //Gastroenterol. Hepatol. 2007. Vol. 30, No. 9. P. 518–524. DOI: 10.1157/13111682

[101] Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn’s disease. Inflamm Bowel Dis. 2004;10(5):573–577. DOI: 10.1097/00054725-200409000-00011

[102] Di Sabatino A., Ciccocioppo R., Armellini E. et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn’s disease// Inflamm. Bowel Dis. 2004. Vol. 10, No. 5. P. 573–577. DOI: 10.1097/00054725-200409000-00011

[103] Shchukina OB. Differential diagnostic and prognostic criteria of clinical forms of Crohn’s disease [dissertation]. Saint Petersburg; 2017. (In Russ.)

[104] Щукина О.Б. Дифференциально-диагностические и прогностические критерии клинических форм болезни Крона: дисс. канд. мед. наук. Санкт-Петербург, 2017.

[105] Bhatti M, Chapman P, Peters M, et al. Visualising E-selectin in the detection and evaluation of inflammatory bowel disease. Gut. 1998;43(1):40–47. DOI: 10.1136/gut.43.1.40

[106] Bhatti M., Chapman P., Peters M. et al. Visualising E-selectin in the detection and evaluation of inflammatory bowel disease // Gut. 1998. Vol. 43, No. 1. P. 40–47. DOI: 10.1136/gut.43.1.40

[107] Gu P, Theiss A, Han J, Feagins LA. Increased cell adhesion molecules, PECAM-1, ICAM-3, or VCAM-1, Predict increased risk for flare in patients with quiescent inflammatory bowel disease. J Clin Gastroenterol. 2017;51(6):522–527. DOI: 10.1097/MCG.0000000000000618

[108] Gu P., Theiss A., Han J., Feagins L.A. Increased cell adhesion molecules, PECAM-1, ICAM-3, or VCAM-1, Predict increased risk for flare in patients with quiescent inflammatory bowel disease // J. Clin. Gastroenterol. 2017. Vol. 51, No. 6. P. 522–527. DOI: 10.1097/MCG.0000000000000618

[109] Babayeva GH, Babayev ZM. New approach to the estimation of a clinical flow in patients with ulceratıve colitis and Crohn’s disease. Experimental and Clinical Gastroenterology. 2019;(2(162)):19–23. (In Russ.). DOI: 10.31146/1682-8658-ecg-162-2-19-23

[110] Бабаева Г.Г., Бабаев З.М. Новый подход к оценке клинического состояния больных с язвенным колитом и болезнью Крона // Экспериментальная и клиническая гастроэнтерология. 2019. № 2(162). С. 19–23. DOI: 10.31146/1682-8658-ecg-162-2-19-23

[111] Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005;100(4):886–895. DOI: 10.1111/j.1572-0241.2005.41469.x

[112] Danese S., Sgambato A., Papa A. et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease //Am. J. Gastroenterol. 2005. Vol. 100, No. 4. P. 886–895. DOI: 10.1111/j.1572-0241.2005.41469.x

[113] Xu G, Tian KL, Liu GP, et al. Clinical significance of plasma D-dimer and von Willebrand factor levels in patients with ulcer colitis. World J Gastroenterol. 2002;8(3):575–576. DOI: 10.3748/wjg.v8.i3.575

[114] Xu G., Tian K.L., Liu G.P. et al. Clinical significance of plasma D-dimer and von Willebrand factor levels in patients with ulcer colitis // World J. Gastroenterol. 2002. Vol. 8, No. 3. P. 575–576. DOI: 10.3748/wjg.v8.i3.575

[115] Cibor D, Szczeklik K, Kozioł K,et al. Serum concentration of selected biochemical markers of endothelial dysfunction and inflammation in patients with varying activities of inflammatory bowel disease. Pol Arch Intern Med. 2020;130(7–8):598–606. DOI: 10.20452/pamw.15463

[116] Cibor D., Szczeklik K., Kozioł K. et al. Serum concentration of selected biochemical markers of endothelial dysfunction and inflammation in patients with varying activities of inflammatory bowel disease // Pol. Arch. Intern. Med. 2020. Vol.130, No. 7–8. P. 598–606. DOI: 10.20452/pamw.15463

[117] Magro F, Araujo F, Pereira P, et al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49(7–8):1265–1274. DOI: 10.1023/b:ddas.0000037822.55717.31

[118] Magro F., Araujo F., Pereira P. etal. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease // Dig. Dis. Sci. 2004. Vol. 49, No. 7–8. P. 1265–1274. DOI: 10.1023/b:ddas.0000037822.55717.31

[119] Principi M, Mastrolonardo M, Scicchitano P, et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis. 2013;7(10):e427–433. DOI: 10.1016/j.crohns.2013.02.001

[120] Principii M., Mastrolonardo M., Scicchitano P. et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases // J. Crohns Colitis. 2013. Vol. 7, No. 10. P. e427–433. DOI: 10.1016/j.crohns.2013.02.001

[121] Caliskan Z, Keles N, Kahraman R, et al. Imparied retrobulbar blood flow and increased carotid IMT in patients with crohn’s disease. Int J Cardiovasc Imaging. 2016;32(11):1617–1623. DOI: 10.1007/s10554-016-0956-3

[122] Caliskan Z., Keles N., Kahraman R. et al. Imparied retrobulbar blood flow and increased carotid IMT in patients with Crohn’s disease // Int. J. Cardiovasc. Imaging. 2016. Vol. 32, No. 11. P. 1617–1623. DOI: 10.1007/s10554-016-0956-3

[123] Bonnin P, Coelho J, Pocard M, et al. Anti-TNFα therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active crohn’s disease. J Crohns Colitis. 2013;7(6):451–459. DOI: 10.1016/j.crohns.2012.07.002

[124] Bonnin P., Coelho J., Pocard M. et al. Anti-TNFα therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active crohn’s disease //J. Crohns Colitis. 2013. Vol. 7, No. 6. P. 451–459. DOI: 10.1016/j.crohns.2012.07.002

[125] Verma I, Syngle A, Krishan P, Garg N. Endothelial progenitor cells as a marker of endothelial dysfunction and atherosclerosis in ankylosing spondylitis: a cross-sectional study. Int J Angiol. 2017;26(1):36–42. DOI: 10.1055/s-0036-1593445

[126] Verma I., Syngle A., Krishan P., Garg N. Endothelial progenitor cells as a marker of endothelial dysfunction and atherosclerosis in ankylosing spondylitis: a cross-sectional study // Int. J. Angiol. 2017. Vol. 26, No. 1. P. 36–42. DOI: 10.1055/s-0036-1593445

[127] Ikdahl E, Hisdal J, Rollefstad S, et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther. 2015;17:279. DOI: 10.1186/s13075-015-0795-y

[128] Ikdahl E., Hisdal J., Rollefstad S. et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study // Arthritis Res. Ther. 2015. Vol. 17. P. 279. DOI: 10.1186/s13075-015-0795-y

[129] Erre GL, Sanna P, Zinellu A, et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol. 2011;30(1):21–27. DOI: 10.1007/s10067-010-1589-x

[130] Erre G.L., Sanna P., Zinellu A. et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study // Clin. Rheumatol. 2011. Vol. 30, No. 1. P. 21–27. DOI: 10.1007/s10067-010-1589-x

[131] Sari I, Kebapcilar L, Alacacioglu A, et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med. 2009;48(16):1363–1368. DOI: 10.2169/internalmedicine.48.2193

[132] Sari I., Kebapcilar L., Alacacioglu A. et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis // Intern. Med. 2009. Vol. 48, No. 16. P. 1363–1368. DOI: 10.2169/internalmedicine.48.2193

[133] Inci U, Yildiz A, Batmaz I, Tekbas E. Assessment of serum asymmetric dimethylarginine levels and left ventricular diastolic function in patients with ankylosing spondylitis. Int J Rheum Dis. 2017;20(2):238–244. DOI: 10.1111/1756-185X.12608

[134] Inci U., Yildiz A., Batmaz I., Tekbas E. Assessment of serum asymmetric dimethylarginine levels and left ventricular diastolic function in patients with ankylosing spondylitis // Int. J. Rheum. Dis. 2017. Vol. 20, No. 2. P. 238–244. DOI: 10.1111/1756-185X.12608

[135] Berg IJ, van der Heijde D, Dagfinrud H, et al. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol. 2015;42(4):645–653. DOI: 10.3899/jrheum.141018

[136] Berg I.J., van der Heijde D., Dagfinrud H. et al. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study // J. Rheumatol. 2015. Vol. 42, No. 4. P. 645–653. DOI: 10.3899/jrheum.141018

[137] Maslyanskiy AL, Zvartau NE, Kolesova EP, et al. Endothelial function in patients with rheumatologic diseases. Arterial Hypertension. 2015;21(2):168–180. (In Russ.). DOI: 10.18705/1607-419X-2015-21-2-168-180

[138] Маслянский А.Л., Звартау Н.Э., Колесова Е.П. и др. Оценка функционального состояния эндотелия у больных ревматологическими заболеваниями // Артериальная гипертензия. 2015. Т. 21, № 2. С. 168–180. DOI: 10.18705/1607-419X-2015-21-2-168-180

[139] Onmaz DE, Isik K, Sivrikaya A, et al. Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis. Amino Acids. 2021;53(9):1329–1338. DOI: 10.1007/s00726-021-03046-z

[140] Onmaz D.E., Isik K., Sivrikaya A. et al. Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis // Amino Acids. 2021. Vol. 53, No. 9. P. 1329–1338. DOI: 10.1007/s00726-021-03046-z

[141] Kemény-Beke Á, Gesztelyi R, Bodnár N, et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine. 2011;78(2):184–187. DOI: 10.1016/j.jbspin.2010.05.009

[142] Kemény-Beke Á., Gesztelyi R., Bodnár N. et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters // Joint Bone Spine. 2011. Vol. 78, No. 2. P. 184–187. DOI: 10.1016/j.jbspin.2010.05.009

[143] Genre F, López-Mejías R, Rueda-Gotor J, et al. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy. Biomed Res Int. 2014;2014:671061. DOI: 10.1155/2014/671061

[144] Genre F., López-Mejías R., Rueda-Gotor J. et al. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy // Biomed. Res. Int. 2014. Vol. 2014. P. 671061. DOI: 10.1155/2014/671061

[145] Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003;132(1):158–162. DOI: 10.1046/j.1365-2249.2003.02101.x

[146] Drouart M., Saas P., Billot M. et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies // Clin. Exp. Immunol. 2003. Vol. 132, No. 1. P. 158–162. DOI: 10.1046/j.1365-2249.2003.02101.x

[147] Pedersen SJ, Sørensen IJ, Lambert RG, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum. 2011;63(12):3789–3800. DOI: 10.1002/art.30627

[148] Pedersen S.J., Sørensen I.J., Lambert R.G. et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover // Arthritis Rheum. 2011. Vol. 63, No. 12. P. 3789–3800. DOI: 10.1002/art.30627

[149] Hindryckx P, Laukens D, Serry G, et al. Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype. Ann Rheum Dis. 2011;70(11):2044–2048. DOI: 10.1136/ard.2010.149229

[150] Hindryckx P., Laukens D., Serry G. et al. Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype // Ann. Rheum. Dis. 2011. Vol. 70, No. 11. P. 2044–2048. DOI: 10.1136/ard.2010.149229

[151] Genre F, López-Mejías R, Miranda-Filloy JA, et al. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. Rheumatol Int. 2015;35(12):2069–2078. DOI: 10.1007/s00296-015-3314-1

[152] Genre F., López-Mejías R., Miranda-Filloy J.A. et al. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients // Rheumatol. Int. 2015. Vol. 35, No. 12. P. 2069–2078. DOI: 10.1007/s00296-015-3314-1

[153] Surdacki A, Sulicka J, Korkosz M, et al. Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis. J Rheumatol. 2014;41(3):481–489. DOI: 10.3899/jrheum.130803

[154] Surdacki A., Sulicka J., Korkosz M. et al. Blood monocyte heterogeneity and markers of endothelial activation in ankylosing spondylitis // J. Rheumatol. 2014. Vol. 41, No. 3. P. 481–489. DOI: 10.3899/jrheum.130803

[155] Das S, Sarkar R, Paul R, et al. Disease activity in spondyloarthropathy: Does it affect Vascular Health? J Assoc Physicians India. 2018;66(7):63–66.

[156] Das S., Sarkar R., Paul R. et al. Disease activity in spondyloarthropathy: Does it affect Vascular Health? //J. Assoc. Physicians India. 2018. Vol. 66, No. 7. P. 63–66.

[157] Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2005;45(3):283–286. DOI: 10.1093/rheumatology/kei145

[158] Sari I., Okan T., Akar S. et al. Impaired endothelial function in patients with ankylosing spondylitis // Rheumatology (Oxford). 2005. Vol. 45, No. 3. P. 283–286. DOI: 10.1093/rheumatology/kei145

[159] Aydoğan Baykara R, Küçük A, Tuzcu A, et al. The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis. Turk J Med Sci. 2021;51(4):1865–1874. DOI: 10.3906/sag-2012-351

[160] Aydoğan Baykara R., Küçük A., Tuzcu A. et al. The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis // Turk. J. Med. Sci. 2021. Vol. 51, No. 4. P. 1865–1874. DOI: 10.3906/sag-2012-351

[161] Przepiera-Będzak H, Fischer K, Brzosko M. Extra-articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis. Mediators Inflamm. 2016;2016:7617954. DOI:10.1155/2016/7617954

[162] Przepiera-Będzak H., Fischer K., Brzosko M. Extra-articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis // Mediators Inflamm. 2016. Vol. 2016. P. 7617954. DOI:10.1155/2016/7617954

[163] Przepiera-Będzak H, Fischer K, Brzosko M. Axial spondyloarthritis and inflammatory bowel disease: Association between disease activity and endothelial dysfunction markers. Rheumatol Int. 2021;42(2):273–277. DOI: 10.1007/s00296-021-04940-1

[164] Przepiera-Będzak H., Fischer K., Brzosko M. Axial spondyloarthritis and inflammatory bowel disease: Association between disease activity and endothelial dysfunction markers //Rheumatol. Int. 2021. Vol. 42, No. 2. P. 273–277. DOI: 10.1007/s00296-021-04940-1

[165] Bandinelli F, Milia A, Manetti M, et al. Lymphatic endothelial progenitor cells and vascular endothelial growth factor-C in spondyloarthritis and Crohn’s disease: two overlapping diseases? Clin Exp Rheumatol. 2015;33(2):195–200.

[166] Bandinelli F., Milia A., Manetti M. et al. Lymphatic endothelial progenitor cells and vascular endothelial growth factor-C in spondyloarthritis and Crohn’s disease: two overlapping diseases? // Clin. Exp. Rheumatol. 2015. Vol. 33, No. 2. P. 195–200.

[167] Cibor D, Domagala-Rodacka R, Rodacki T, et al. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol. 2016;22(3):1067–1077. DOI: 10.3748/wjg.v22.i3.1067

[168] Cibor D., Domagala-Rodacka R., Rodacki T. et al. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications // World J. Gastroenterol. 2016. Vol. 22, No. 3. P. 1067–1077. DOI: 10.3748/wjg.v22.i3.1067

RIGHTS & PERMISSIONS

Eco-Vector